154 related articles for article (PubMed ID: 25509993)
1. [Therapeutic use of immune sera. Ebola survivors as lifesavers?].
Eickmann M; Schumacher B
MMW Fortschr Med; 2014 Nov; 156(19):6. PubMed ID: 25509993
[No Abstract] [Full Text] [Related]
2. Do therapeutic antibodies hold the key to an effective treatment for Ebola hemorrhagic fever?
Takada A
Immunotherapy; 2013 May; 5(5):441-3. PubMed ID: 23638738
[No Abstract] [Full Text] [Related]
3. Ethical dilemma for Ebola drug trials.
Hayden EC
Nature; 2014 Nov; 515(7526):177-8. PubMed ID: 25391940
[No Abstract] [Full Text] [Related]
4. Profile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu).
Sobarzo A; Groseth A; Dolnik O; Becker S; Lutwama JJ; Perelman E; Yavelsky V; Muhammad M; Kuehne AI; Marks RS; Dye JM; Lobel L
J Infect Dis; 2013 Jul; 208(2):299-309. PubMed ID: 23585686
[TBL] [Abstract][Full Text] [Related]
5. Protective efficacy of neutralizing antibodies against Ebola virus infection.
Takada A; Ebihara H; Jones S; Feldmann H; Kawaoka Y
Vaccine; 2007 Jan; 25(6):993-9. PubMed ID: 17055127
[TBL] [Abstract][Full Text] [Related]
6. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody.
Corti D; Misasi J; Mulangu S; Stanley DA; Kanekiyo M; Wollen S; Ploquin A; Doria-Rose NA; Staupe RP; Bailey M; Shi W; Choe M; Marcus H; Thompson EA; Cagigi A; Silacci C; Fernandez-Rodriguez B; Perez L; Sallusto F; Vanzetta F; Agatic G; Cameroni E; Kisalu N; Gordon I; Ledgerwood JE; Mascola JR; Graham BS; Muyembe-Tamfun JJ; Trefry JC; Lanzavecchia A; Sullivan NJ
Science; 2016 Mar; 351(6279):1339-42. PubMed ID: 26917593
[TBL] [Abstract][Full Text] [Related]
7. Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.
Gupta M; Mahanty S; Bray M; Ahmed R; Rollin PE
J Virol; 2001 May; 75(10):4649-54. PubMed ID: 11312335
[TBL] [Abstract][Full Text] [Related]
8. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.
Parren PW; Geisbert TW; Maruyama T; Jahrling PB; Burton DR
J Virol; 2002 Jun; 76(12):6408-12. PubMed ID: 12021376
[TBL] [Abstract][Full Text] [Related]
9. A glimpse into immune responses evolving against Ebola virus.
Saphire EO
Nat Med; 2019 Oct; 25(10):1470-1471. PubMed ID: 31591604
[No Abstract] [Full Text] [Related]
10. Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections.
Kudoyarova-Zubavichene NM; Sergeyev NN; Chepurnov AA; Netesov SV
J Infect Dis; 1999 Feb; 179 Suppl 1():S218-23. PubMed ID: 9988187
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Ebola virus infection with antibodies from reconvalescent donors.
Kreil TR
Emerg Infect Dis; 2015 Mar; 21(3):521-3. PubMed ID: 25695274
[TBL] [Abstract][Full Text] [Related]
12. Antibody therapeutics for Ebola virus disease.
Zeitlin L; Whaley KJ; Olinger GG; Jacobs M; Gopal R; Qiu X; Kobinger GP
Curr Opin Virol; 2016 Apr; 17():45-49. PubMed ID: 26826442
[TBL] [Abstract][Full Text] [Related]
13. Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus.
Howell KA; Brannan JM; Bryan C; McNeal A; Davidson E; Turner HL; Vu H; Shulenin S; He S; Kuehne A; Herbert AS; Qiu X; Doranz BJ; Holtsberg FW; Ward AB; Dye JM; Aman MJ
Cell Rep; 2017 Apr; 19(2):413-424. PubMed ID: 28402862
[TBL] [Abstract][Full Text] [Related]
14. Correspondence of Neutralizing Humoral Immunity and CD4 T Cell Responses in Long Recovered Sudan Virus Survivors.
Sobarzo A; Stonier SW; Herbert AS; Ochayon DE; Kuehne AI; Eskira Y; Fedida-Metula S; Tali N; Lewis EC; Egesa M; Cose S; Lutwama JJ; Yavelsky V; Dye JM; Lobel L
Viruses; 2016 May; 8(5):. PubMed ID: 27187443
[TBL] [Abstract][Full Text] [Related]
15. Sudan ebolavirus long recovered survivors produce GP-specific Abs that are of the IgG1 subclass and preferentially bind FcγRI.
Radinsky O; Edri A; Brusilovsky M; Fedida-Metula S; Sobarzo A; Gershoni-Yahalom O; Lutwama J; Dye J; Lobel L; Porgador A
Sci Rep; 2017 Jul; 7(1):6054. PubMed ID: 28729706
[TBL] [Abstract][Full Text] [Related]
16. Emergence of Ebola Virus Escape Variants in Infected Nonhuman Primates Treated with the MB-003 Antibody Cocktail.
Kugelman JR; Kugelman-Tonos J; Ladner JT; Pettit J; Keeton CM; Nagle ER; Garcia KY; Froude JW; Kuehne AI; Kuhn JH; Bavari S; Zeitlin L; Dye JM; Olinger GG; Sanchez-Lockhart M; Palacios GF
Cell Rep; 2015 Sep; 12(12):2111-20. PubMed ID: 26365189
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee.
Mupapa K; Massamba M; Kibadi K; Kuvula K; Bwaka A; Kipasa M; Colebunders R; Muyembe-Tamfum JJ
J Infect Dis; 1999 Feb; 179 Suppl 1():S18-23. PubMed ID: 9988160
[TBL] [Abstract][Full Text] [Related]
18. An update on the use of antibodies against the filoviruses.
Saphire EO
Immunotherapy; 2013 Nov; 5(11):1221-33. PubMed ID: 24188676
[TBL] [Abstract][Full Text] [Related]
19. Feverish Quest for Ebola Immunotherapy: Straight or Cocktail?
Saphire EO; Aman MJ
Trends Microbiol; 2016 Sep; 24(9):684-686. PubMed ID: 27338027
[TBL] [Abstract][Full Text] [Related]
20. The emergence of antibody therapies for Ebola.
Hiatt A; Pauly M; Whaley K; Qiu X; Kobinger G; Zeitlin L
Hum Antibodies; 2015 Dec; 23(3-4):49-56. PubMed ID: 27472862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
